Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STING1 | Q86WV6 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | IRAK4 | Q9NWZ3 | 14/20 | 0.35 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.33 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4565058 | 0.94 | MMP2 (0.38) | STING1CYP3A4IRAK4 | |
| SCHEMBL1074490 | 0.90 | CYP3A4 (0.40) | STING1CYP3A4IRAK4 | |
| SCHEMBL1074488 | 0.90 | CYP3A4 (0.40) | STING1CYP3A4IRAK4 | |
| Hydrochloric Acid SCHEMBL1071141 | 0.87 | IRAK4 (0.39) | STING1IRAK4 | |
| SCHEMBL4301154 | 0.86 | APAF1 (0.39) | CYP3A4IRAK4HCRTR1HCRTR2 | |
| SCHEMBL16318483 | 0.83 | CYP3A4 (0.41) | CYP3A4IRAK4 | |
| SCHEMBL16318484 | 0.83 | CYP3A4 (0.41) | CYP3A4IRAK4 | |
| SCHEMBL2743957 | 0.82 | HCRTR1 (0.35) | CYP3A4IRAK4HCRTR1HCRTR2 | |
| SCHEMBL4298045 | 0.79 | CYP3A4 (0.38) | CYP3A4IRAK4 | |
| SCHEMBL2897360 | 0.79 | SMN1; SMN2 (0.40) | STING1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8314062-B2 | Macrocyclic compounds as antiviral agents | INSTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2012-11-20 | — | — | US | disclosed |
| US-20090312241-A1 | Macrocyclic Compounds as Antiviral Agents | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2009-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312241-A1 | Macrocyclic Compounds as Antiviral Agents | ZC3HAV1, ZC3HAV1L, HAVCR2 | STING1 1120/4885CYP3A4 338/4885IRAK4 1025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.